1 / 51

Antiviral Drug Products Advisory Committee Meeting

Antiviral Drug Products Advisory Committee Meeting. NDA 21-266 voriconazole tablets NDA 21-267 voriconazole for injection Rosemary Tiernan, MD, MPH. Division of Special Pathogen and Immunologic Drug Products Voriconazole Review Team. Jouhayna Saliba, RPh Marc Cavaillé-Coll, MD, PhD

alain
Download Presentation

Antiviral Drug Products Advisory Committee Meeting

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Antiviral Drug Products Advisory Committee Meeting NDA 21-266 voriconazole tablets NDA 21-267 voriconazole for injection Rosemary Tiernan, MD, MPH

  2. Division of Special Pathogen and Immunologic Drug ProductsVoriconazole Review Team Jouhayna Saliba, RPhMarc Cavaillé-Coll, MD, PhD Gene W. Holbert, PhD Norman R. Schmuff, PhD Owen G. McMaster, PhD Kenneth L. Hastings, PhD Linda L. Gosey, MS Shukal Bala, PhD Philip M.Colangelo, PharmD, PhD Funmi O. Ajayi, PhD Joette M. Meyer,PharmD Wiley A. Chambers, MD Cheryl A. Dixon, PhD Karen M. Higgins, ScD M. Regina Alivisatos, MD Edward M. Cox, MD, MPH Rosemary Johann-Liang, MD Rigoberto A. Roca, MD John H. Powers III, MD Rosemary Tiernan, MD, MPH

  3. Indications Requested in the NDA Treatment of invasive aspergillosis Empiric antifungal therapy of febrile neutropenic patients Treatment of: -candida esophagitis -serious candida infections -serious fungal infections due to Fusarium and Scedosporium spp. -serious fungal infections in patients refractory or intolerant to other therapy

  4. FDA Presentation Treatment of Invasive Aspergillosis Empiric Antifungal Therapy of Febrile Neutropenic Patients Clinical Safety Questions to the Advisory Committee

  5. Treatment of Invasive Aspergillosis Study 307/602 Study 304 and Historical Control Study 1003

  6. Treatment of Invasive Aspergillosis • Study 307/602 • Randomized, controlled, open-label, initial therapy • Blinded Data Review Committee • voriconazole vs. amphotericin B followed by “other licensed antifungal therapy” (OLAT) • Study 304 • Uncontrolled study of primary and salvage cases • Expert Panel • Retrospectively designed historical control

  7. Study 307/602 • MITT • voriconazole (N = 144) • amphotericin B (N = 133) • Patient Characteristics • White male, hematologic malignancies, pulmonary site • Switch to OLAT • voriconazole 36.1% • amphotericin B 80.5%

  8. Study 307/602Primary Efficacy Endpoint • Satisfactory Response at Week 12 (MITT) • voriconazole 76/144 52.8% • ampho B 42/133 31.6% • 95% CI stratified by protocol (9.6, 33.6)

  9. Study 307/602Additional Efficacy Analyses • Not allowing DRC to upgrade investigator assessment • vori 46.5% vs. ampho B 29.3% • “Modified Week 12” • vori 45.1% vs. ampho B 31.6% • Week 16 follow-up • vori 45.8% vs ampho B 33.1%

  10. Study 307/602Survival • Probability of Survival at Day 84 • vori 0.708 • ampho B 0.579

  11. Study 304 • Expert Evaluable Population • Overall N = 112 • Primary therapy N = 58 • Salvage therapy N = 54 • Patient Characteristics • White male, hematologic malignancies, pulmonary site, European population

  12. Study 304 • Expert Global Response at EOT (expert evaluable population) • Overall 55/112 49.1% • Primary 35/58 60.3% • Salvage 20/54 37.0%

  13. Historical Control (HC)Study 1003 • Substantial effort to provide the most comparable population to primary therapy patients in Study 304 • primary therapy was <5 days prior antifungal therapy • Matched on certainty of diagnosis, underlying disease, and site of infection

  14. Study 304/ Historical Control Study 1003 • Global Response • Study 304 vori 26/50 52.0% • Historical Control 23/92 25.0% • Probability of Survival at Day 90 • Study 304 vori 0.554 • Historical Control 0.417

  15. Historical Control Issues • Patient populations • Study 304 only in Europe • Historical Control both in Europe and US • Global Response • US HC 11/51 21.6% • EU HC 12/41 29.3% • Study 304 vori 26/50 52.0% • Probability of Survival at Day 90 • US HC 0.290 • EU HC 0.573 • Study 304 vori 0.554

  16. Historical Control Issues (cont.) • Duration of treatment • longer for voriconazole treated patients • Difference in inclusion/exclusion criteria • which could possibly allow for sicker patients in the HC

  17. Aspergillosis Summary • HC good effort but still concerns about comparability of the study populations • Study 304 results are used to support the randomized controlled study • Study 307/602showed • Non-inferior Global Response • Statistically superior • Survival Benefit

  18. Clinical Safety Rosemary Tiernan, MD, MPH

  19. Clinical Safety • Focus on 5 specific areas: • Ocular safety • Cardiac safety • Hepatic safety • Rash • Drug interactions

  20. Clinical Safety • Focus on 5 specific areas: • Ocular safety • Cardiac safety • Hepatic safety • Rash • Drug interactions

  21. Ocular Safety • Pre-clinical studies • Incidence in clinical studies is 1 out of every 3 subjects • Symptoms Decreased vision, photophobia, altered color perception and ocular discomfort • Unknown Mechanism • No human histopathology • Ocular biomicroscopy has not detected ocular lesions

  22. Ocular safety Results from study 150-1004 • Effects noted in • ERG • Farnsworth-Munsell 100 hue test (color vision) • Humphrey Perimetry (visual field) • Drug effect on both rod and cone function • Decreased vision on day 1 and continued through 28 days of therapy • Testing 2 weeks after the end of treatment demonstrated return to normal function

  23. Ocular Safety Additional issues regarding use of this drug -re-challenge or re-treatments -ocular development in pediatric patients -patients with underlying eye disease -treatment beyond 28 days

  24. Clinical Safety • Focus on 5 specific areas: • Ocular safety • Cardiac safety • Hepatic safety • Rash • Drug interactions

  25. Cardiac Safety • In vitro data • In vivo data • Clinical data • One sudden death

  26. Cardiac Safety • Clinical data • Adverse Events • Cardiac arrhthymias, CHF, cardiac arrests • Discontinuations

  27. Clinical Safety • Focus on 5 specific areas: • Ocular safety • Cardiac safety • Hepatic safety • Rash • Drug interactions

  28. Hepatic Safety Summary • Phase I/II Studies • Positive dose (exposure) response with ALT and AST • Phase III Comparative Studies • Hepatic adverse events and ALT & AST abnormalities were more frequent with voriconazole than fluconazole • Frequency of hepatic adverse effects similar between voriconazole and amphotericin B formulations studied • Serious hepatic adverse events reported more frequently in voriconazole treated patients.

  29. Clinical Safety • Focus on 5 specific areas: • Ocular safety • Cardiac safety • Hepatic safety • Rash • Drug interactions

  30. Rash • Difficulties in assessment of rash include: • Concomitant medications that can also cause rash • Concomitant medications can affect the type or severity of skin exanthem observed • Underlying conditions such as GVHD

  31. Rash Observed in 18.6% of patients on voriconazole in therapeutic studies program • Most rashes mild to moderate • No major differences in discontinuations for rash • 4 non-fatal cases of Stevens-Johnson

  32. Clinical Safety • Focus on 5 specific areas: • Ocular safety • Cardiac safety • Hepatic safety • Rash • Drug interactions

  33. Drug Interactions with VoriconazoleIn Vitro Metabolism • Voriconazole is a substrate and inhibitor of CYP2C19, CYP2C9, CYP3A4 • Substrate affinity and inhibition potency of voriconazole is greater for CYP2C19 and CYP2C9 compared to CYP3A4 • CYP3A4 inhibition potency of voriconazole weaker than ketoconazole and itraconazole • Potency of voriconazole to inhibit CYP3A4 metabolism varies among several CYP3A4 substrates (and vice-versa) • HIV-PI, NNRTI, and Immunosuppressant Drugs

  34. Drug Interactions with VoriconazoleIn Vivo Metabolism • Representative substrates / inhibitors / inducers of the three CYP enzymes were studied, since it is not possible to evaluate every potential drug interaction • Example: HIV-PI and NNRTI drugs not studied in vivo • CYP3A4 inhibitors and/or inducers • Exception: Indinavir  no significant interaction • The potential for drug interactions with voriconazole presents a therapeutic challenge for the prescriber

  35. Clinical Safety Rosemary Tiernan, MD, MPH

  36. Clinical Safety • Focus on 5 specific areas: • Ocular safety • Cardiac safety • Hepatic safety • Rash • Drug interactions

  37. Clinical Safety • Focus on 5 specific areas: • Ocular safety • Cardiac safety • Hepatic safety • Rash • Drug interactions

  38. Ocular Safety • Pre-clinical studies • Incidence in clinical studies is 1 out of every 3 subjects • Symptoms Decreased vision, photophobia, altered color perception and ocular discomfort • Unknown Mechanism • No human histopathology • Ocular biomicroscopy has not detected ocular lesions

  39. Ocular safety Results from study 150-1004 • Effects noted in • ERG • Farnsworth-Munsell 100 hue test (color vision) • Humphrey Perimetry (visual field) • Drug effect on both rod and cone function • Decreased vision on day 1 and continued through 28 days of therapy • Testing 2 weeks after the end of treatment demonstrated return to normal function

  40. Ocular Safety Additional issues regarding use of this drug -re-challenge or re-treatments -ocular development in pediatric patients -patients with underlying eye disease -treatment beyond 28 days

  41. Clinical Safety • Focus on 5 specific areas: • Ocular safety • Cardiac safety • Hepatic safety • Rash • Drug interactions

  42. Cardiac Safety • In vitro data • In vivo data • Clinical data • One sudden death

  43. Cardiac Safety • Clinical data • Adverse Events • Cardiac arrhthymias, CHF, cardiac arrests • Discontinuations

  44. Clinical Safety • Focus on 5 specific areas: • Ocular safety • Cardiac safety • Hepatic safety • Rash • Drug interactions

  45. Hepatic Safety Summary • Phase I/II Studies • Positive dose (exposure) response with ALT and AST • Phase III Comparative Studies • Hepatic adverse events and ALT & AST abnormalities were more frequent with voriconazole than fluconazole • Frequency of hepatic adverse effects similar between voriconazole and amphotericin B formulations studied • Serious hepatic adverse events reported more frequently in voriconazole treated patients.

  46. Clinical Safety • Focus on 5 specific areas: • Ocular safety • Cardiac safety • Hepatic safety • Rash • Drug interactions

  47. Rash • Difficulties in assessment of rash include: • Concomitant medications that can also cause rash • Concomitant medications can affect the type or severity of skin exanthem observed • Underlying conditions such as GVHD

  48. Rash Observed in 18.6% of patients on voriconazole in therapeutic studies program • Most rashes mild to moderate • No major differences in discontinuations for rash • 4 non-fatal cases of Stevens-Johnson

  49. Clinical Safety • Focus on 5 specific areas: • Ocular safety • Cardiac safety • Hepatic safety • Rash • Drug interactions

  50. Drug Interactions with VoriconazoleIn Vitro Metabolism • Voriconazole is a substrate and inhibitor of CYP2C19, CYP2C9, CYP3A4 • Substrate affinity and inhibition potency of voriconazole is greater for CYP2C19 and CYP2C9 compared to CYP3A4 • CYP3A4 inhibition potency of voriconazole weaker than ketoconazole and itraconazole • Potency of voriconazole to inhibit CYP3A4 metabolism varies among several CYP3A4 substrates (and vice-versa) • HIV-PI, NNRTI, and Immunosuppressant Drugs

More Related